SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research in the October 3, 2023 issue of the American Heart Association’s (AHA) journal, Circulation.

南旧金山，加利福尼亚州，2023年10月2日（GLOBE NEWSWIRE）-Tenaya Therapeutics，Inc。（纳斯达克股票代码：TNYA），一家临床阶段生物技术公司，致力于发现，开发和提供潜在的治疗方法解决心脏病的根本原因，今天宣布于10月3日发表临床前研究，2023年美国心脏协会（AHA）杂志，发行。

The article, titled “Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus,” details Tenaya’s initial success in cardiac cellular regeneration utilizing a single adeno-associated viral (AAV) vector to deliver specific combinations of genes to reprogram cells in the heart following ischemic injury.

这篇文章题为“使用在单一新型腺相关病毒中递送的优化的心脏重编程混合物改善缺血后大鼠的心脏功能”，详细介绍了Tenaya利用单一腺相关病毒（AAV）载体在心脏细胞再生中的初步成功以递送特定的基因组合以在缺血性损伤后重编程心脏中的细胞。

“In an effort to restore contraction to a heart weakened by myocardial infarction, we’ve developed an elegant approach to reprogram select cardiac cells that combines specific genes and regulatory elements into a single adeno-associated vector. Using this approach in a model of chronic ischemic injury we successfully achieved – for the first time – dose-dependent and durable improvements in heart function through cardiac regeneration,” said Tim Hoey, Ph.D., Chief Scientific Officer of Tenaya.

“为了恢复心肌梗塞减弱的心脏的收缩，我们开发了一种优雅的方法来重新编程选择的心脏细胞，将特定的基因和调控元件组合成一个单一的腺相关载体，在慢性缺血性模型中使用这种方法我们成功实现了首次剂量依赖性和持久性的改善Tenaya首席科学官Tim Hoey博士说。

“Significant molecular engineering challenges needed to be overcome to make cardiac cellular regeneration feasible for therapeutic development and this work represents a major step forward in advancing the potential application of our cellular reprogramming approach in a clinical setting.” An estimated four million people in the U.S.

“需要克服重大的分子工程挑战，使心脏细胞再生可行的治疗发展，这项工作是向前迈出的一大步，推进我们的细胞重编程方法在临床上的潜在应用。”估计有400万人在美国。

are living with heart failure associated with a prior heart attack, or myocardial infarction (MI). When an MI occurs, cardiomyocytes (CMs), the he.

患有与先前的心脏病发作或心肌梗塞（MI）相关的心力衰竭。当MI发生时，心肌细胞（CM），he。